Highlights from EAU 2017 - Results from #100

Viewing 101-120 of 138 articles

EAU 2017: Debate on bladder cancer surgery: open cystectomy is still the way - Con

EAU 2017: Debate on prostate cancer surgery: radical prostatectomy should be performed with robot - Con

EAU 2017: The argument for surgical management of high-risk prostate cancer

EAU 2017: Circulating Tumor Cells in Prostate Cancer: A Marker?

EAU 2017: The role of surgery in metastatic renal cancer

EAU 2017: Observation or active surveillance or curative treatment: What do SPCG-4 data tell us?

EAU 2017: Prospective validation of active surveillance: PRIAS

EAU 2017: Observation or active surveillance or curative treatment: What do PIVOT data tell us?

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Imaging-based biomarkers: mpMRI

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Tissue-based biomarkers: CCP

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Blood and urine-based biomarkers

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: The role of miRNA in oncogenesis and progression

EAU 2017: Special session of the Prostate Cancer Prevention Group - Risk factors and biomarkers for screening and triage: Dietary and lifestyle factors

EAU 2017: Special session of the Prostate Cancer Prevention Group: PLCO

EAU 2017: Special session of the Prostate Cancer Prevention Group: ERSPC

EAU 2017: Special session of the Prostate Cancer Prevention Group: ProtecT

EAU 2017: Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial

EAU 2017: Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial

EAU 2017: Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder

EAU 2017: Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052

1
2
3
4
5
6
7